Astria Therapeutics
Astria Therapeutics (formerly Catabasis Pharmaceuticals, renamed in September 2021) is a Boston-based biopharmaceutical company whose lead product candidate is navenibart for hereditary angioedema, with STAR-0310 in development for atopic dermatitis. BioCryst Pharmaceuticals completed its acquisition of the company in January 2026.
Key facts
| Company Operating Status | Active |
|---|---|
| Full Address | 100 High Street, 28th Floor, Boston, MA 02110, US |
| Public/Private | Public |
| Stock Symbol | CATB |
| Wellfound ID | catabasis-pharmaceuticals |
| Wikidata ID | Q17143508 |